Publication: The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Loading...
Identifiers
Publication date
2019-11-01
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
Abstract
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM
-/-
patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors.
Description
Keywords
MeSH Terms
DeCS Terms
Bibliographic citation
NPJ Breast Cancer. 2019;5:38.
Collections
Grupos de investigación
IDIBELL - Instituto de Investigación Biomédica de Bellvitge (Cataluña)
IDIS - Instituto de Investigación Sanitaria de Santiago de Compostela (Galicia)
IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (Madrid)
IIB Sant Pau - Instituto de Investigación Sant Pau (Cataluña)
IISGS - Instituto de Investigación Sanitaria Galicia Sur (Galicia)
IDIBELL - Instituto de Investigación Biomédica de Bellvitge (Cataluña)
IDIS - Instituto de Investigación Sanitaria de Santiago de Compostela (Galicia)
IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (Madrid)
IIB Sant Pau - Instituto de Investigación Sant Pau (Cataluña)
IISGS - Instituto de Investigación Sanitaria Galicia Sur (Galicia)